Eli Lilly & Co. (LLY) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardianc...
Eli Lilly & Co. (LLY) currently trades at a P/E ratio of 41.34 (historical range: 30.17–118.20, median: 51.12), placing it at the 18th percentile — cheap relative to its history, P/S ratio of 14.46 (range: 10.56–22.30, 42th percentile — near its historical average), EV/EBITDA of 122.36 (range: 32.06–244.46, 76th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Eli Lilly & Co.'s P/E ratio has contracted by 43% over the observed period (from an average of 77.7 to 44.1).
Eli Lilly & Co. appears fairly valued relative to its historical range, with valuation metrics near their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 41.34 | 30.17 | 51.12 | 118.20 | 18th | cheap relative to its history |
| P/S Ratio | 14.46 | 10.56 | 15.05 | 22.30 | 42th | near its historical average |
| EV/EBITDA | 122.36 | 32.06 | 89.98 | 244.46 | 76th | above its historical average |
| FCF Yield | 0.00 | 0.00 | 0.00 | 0.01 | 37th | above its historical average |